Comparative Pharmacology
Head-to-head clinical analysis: CARDENE IN 5 0 DEXTROSE IN PLASTIC CONTAINER versus DYNACIRC CR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CARDENE IN 5 0 DEXTROSE IN PLASTIC CONTAINER versus DYNACIRC CR.
CARDENE IN 5.0% DEXTROSE IN PLASTIC CONTAINER vs DYNACIRC CR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Nicardipine is a dihydropyridine calcium channel blocker that inhibits the transmembrane influx of calcium ions into vascular smooth muscle and cardiac muscle. It causes vasodilation and decreases systemic vascular resistance.
Dihydropyridine calcium channel blocker that selectively inhibits calcium ion influx across cardiac and vascular smooth muscle cell membranes, leading to vasodilation and reduced peripheral vascular resistance.
Intravenous infusion: initial dose 5 mg/hour, titrate by 2.5-5 mg/hour every 15-30 minutes as needed; maximum 15 mg/hour. Oral: 20 mg three times daily initially, then 30-40 mg three times daily.
Isradipine extended-release (DynaCirc CR) is indicated for hypertension. Initial dose: 5 mg orally once daily. Titrate based on blood pressure response; maximum dose 10 mg once daily.
None Documented
None Documented
2 to 4 hours in healthy subjects; increased in hepatic impairment (up to 7 hours) and in elderly. No significant change in renal impairment.
Terminal half-life approximately 7-8 hours; sustained due to controlled-release formulation.
Primarily hepatic metabolism to inactive metabolites; <1% excreted unchanged in urine. Biliary/fecal excretion of metabolites accounts for approximately 60-70% of total elimination, with renal excretion of metabolites approximately 30-40%.
Primarily hepatic metabolism with biliary excretion; 20% renal, 80% fecal.
Category C
Category C
Calcium Channel Blocker
Calcium Channel Blocker